Researchers are currently investigating whether a combined cannabigerol (CBG) and cannabidiol (CBD) oil may help people experiencing chemotherapy‑induced peripheral neuropathy (CIPN)—a condition that can cause pain, numbness, tingling, and sensitivity in the hands and feet after cancer treatment. This clinical study, registered with the U.S. National Institutes of Health, is designed to understand if CBG/CBD oil may support symptom relief and quality of life for individuals living with CIPN. Unlike laboratory research, this trial involves direct evaluation in human volunteers to assess outcomes in a real‑world clinical setting.

Participants in the study receive CBG/CBD oil and are monitored over time to track changes in neuropathy symptoms, side effects, and overall tolerability of the treatment. The study’s goals include gathering data on the safety profile, patterns of use, and any potential improvements in pain, sensory symptoms, and daily functioning. Because CIPN can be difficult to manage with conventional treatments, researchers are exploring cannabinoids like CBG and CBD as possible supportive options due to their interactions with the nervous system and potential to influence pain‑related pathways.

While results are still forthcoming and have not yet been published, this clinical trial represents an important step in gathering controlled human data on a combined cannabinoid approach for a condition that currently has limited treatment options. The findings may help guide future recommendations for cannabinoid‑based supportive care for people dealing with the long‑term effects of chemotherapy.

Source

CBG/CBD Oil for Chemotherapy-Induced Peripheral Neuropathy. ClinicalTrials.gov Identifier: NCT07016971. National Institutes of Health (NIH). Available at: https://clinicaltrials.gov/study/NCT07016971